Indo Us Bio-Tech Ltd

Indo Us Bio-Tech Ltd has announced the closure of its trading window for all designated persons. This measure is in accordance with the company's Code of Conduct for Prevention of Insider Trading, framed under SEBI regulations. The window will remain closed from October 01, 2026, until 48 hours after the announcement of the unaudited financial results for the quarter and half-year ending September 30, 2026. The specific date for the Board of Directors' meeting to approve these results will be communicated later.

Indo Us Bio-Tech Ltd has filed its Annual Report for the financial year 2025-2026. The report includes the notice for the 22nd Annual General Meeting (AGM), scheduled to be held on Wednesday, September 30, 2026, at 02:30 PM. The AGM will be conducted through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The annual report covers various sections including company profile, corporate information, products, MOUs, milestones, infrastructure, strategic strengths, chairman's message, notice of AGM, e-voting procedures, explanatory statement, directors' report, management discussion and analysis, corporate governance, and financial statements. Key personnel and auditors are also listed.

Indo Us Bio-Tech Ltd has announced that its 22nd Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 02:30 PM IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). Key agenda items include the adoption of audited financial statements for the year ended March 31, 2026, the reappointment of Mrs. Priyanka Samarth Patel as a Director, and the appointment of M/s. Bhagat & Associates as Statutory Auditors for a five-year term. Additionally, the company will seek approval for enhanced borrowing limits.

Indo Us Bio-Tech Ltd announced that its Board of Directors met on September 5, 2026. Key decisions included calling the Annual General Meeting (AGM) for the financial year ended March 31, 2026, on September 30, 2026. The Board also approved the draft Directors' Report and the notice for the 22nd AGM. Additionally, M/s. Bhagat & Associates were proposed as Statutory Auditors for five years, subject to member approval. The book closure date is set from September 23 to September 30, 2026, for the AGM.

Indo Us Bio-Tech Ltd announced its standalone unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the results in a meeting held on August 12, 2026. The financial results were also reviewed by the Audit Committee and the Statutory Auditors provided a limited review report with an unmodified opinion. The company operates primarily in Seed Cultivation, Processing & Trading.

Indo Us Bio-Tech Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The Board of Directors approved these results along with the limited review report from the auditor. The meeting was held on August 12, 2026, at the company's registered office in Ahmedabad. The company operates primarily in Seed Cultivation, Processing & Trading. No investor complaints were pending or received during the period under review.

Indo Us Bio-Tech Ltd has announced that its Board of Directors will convene on August 12, 2026. The primary agenda item is to consider and approve the unaudited financial results for the quarter ended June 30, 2026. Additionally, the board will discuss other corporate matters. The trading window for company insiders, which commenced on July 1, 2026, will remain closed until 48 hours after the dissemination of these financial results.

Indo Us Bio-Tech Ltd has clarified the effective date for the reconstitution of its Board Committees. The composition approved in the Board Meeting of July 10, 2026, is now effective from April 21, 2026, aligning with the appointment and resignation of Directors on that date. The filing details the revised composition of the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee, with specific individuals appointed as Chairperson and Members for each. All other aspects of the July 10, 2026 outcome remain unchanged.

Indo Us Bio-Tech Ltd has announced the resignation of its statutory auditors, M/s. Gautam N Associates, effective June 15, 2026, citing administrative and operational restructuring. The company's Board of Directors, upon recommendation from the Audit Committee, has approved the appointment of M/s. Bhagat & Associates as the new statutory auditor, subject to shareholder approval. The new auditor's term will commence from the date of board approval until the conclusion of the next General Meeting. Details regarding both the outgoing and incoming auditors, as required by SEBI regulations, have been provided.

Indo Us Bio-Tech Ltd announced changes in its Board of Directors' committees following the resignation of Mrs. Nehaben Patel as Non-Executive Independent Director. The Board met on July 10, 2026, to approve these changes. Mrs. Hemanshi Darsh Soni was appointed as an Additional Director (Non-Executive, Independent), subject to shareholder approval. The reconstitution of the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee is effective from July 10, 2026, to ensure compliance with SEBI regulations and the Companies Act.